DENVER, Colo., Feb. 7, 2024 (www.247marketnews.com)- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) reported, this morning, preliminary outcomes of the Company’s dialogue with the U.S. Food and Drug Administration (FDA) on the path to approval of IkT-001Pro in blood cancers, the Company’s prodrug of the anticancer agent imatinib mesylate.
Glatfelter is trading at $3.16, up $0.18 (+11.72%), on 115K shares traded.
Its 52-week range is $0.79 to $5.607. Yesterday’s $3.35 high may be a key inflection point in today’s trading.
“We were pleased with the discussion we had with the FDA as we begin the process of building our first NDA package needed for approval,” said Dr. Milton Werner, President and Chief Executive Officer of Inhibikase. “Our bioequivalence studies were presented to the FDA and we were given specific guidance on the manufacturing requirements necessary to complete the NDA. The FDA acknowledged that the appropriate approval path appears to be 505(b)(2) and we plan to seek all 11 indications for which imatinib mesylate has been approved, including its use in children. There is significant work ahead of us as we discuss these details with potential commercialization partners and carry out the work needed for the NDA submission,” noted Dr. Werner.
Inhibikase website: www.inhibikase.com
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.
The stocks and strategies discussed are simply ideas only and are in no way financial advice or recommendations. The author may or may not at any time be holding securities discussed. The author may or may not enter trades in the stocks mentioned. Some positions in mentioned stocks may already be held or are being adjusted or are simply examples, ideas or discussion topics. You are always trading at your own risk.
Few succeed in the stock market. Don’t trade if you’re not able to devote the necessary time. Earmark your surplus funds that you’re prepared to lose. Assess your risk appetite and set your stops accordingly, and honor your stop losses. Always employ loss limiting strategies. Be prepared to be blindsided by hidden risks, a bad company financing or other move can turn gains into losses.
Learn technical analysis, charting, patterns, and setups. Buying at the bottom and selling at the top is a myth. The middle half of a move is the sweet spot and learn how to exit a winning position, because trying to time the exact top can turn into big losses. Trade small and take advantage of small price move strategies, like scalping.
Remove emotional and psychological biases, and consider that you’re competing against professionals who’re deploying a number of powerful stock market tools. Successful traders make more on their winners than they lose on their losers. Learn how to interpret the ECN/Level 2 data.
24/7 Market News